Form 4: Checkpoint Therapeutics CFO Acquires 540,000 Shares of Restricted Stock

William Garrett Gray, CFO of Checkpoint Therapeutics, acquired 540,000 shares of restricted common stock on May 24, 2024, as part of a vesting schedule.

Summary

• William Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics, Inc. (CKPT), acquired 540,000 shares of restricted common stock on May 24, 2024.
• The acquisition was reported on a Form 4 filing with the SEC.
• The shares were acquired at a price of $0.00.
• Following the transaction, Gray beneficially owns 685,224 shares of Checkpoint Therapeutics, Inc.
• The restricted stock vests in three equal installments: one-third on January 31, 2025, one-third on January 31, 2026, and one-third on January 31, 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard executive compensation practice. The acquisition of shares by an executive is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CFO's acquisition of restricted stock, which is a common form of executive compensation.

Stakeholder Impact

• Shareholders may view the CFO's acquisition of shares as a positive signal of confidence in the company's future.

Key Dates